Name: TriCos Biotherapeutics GmbH
Address: Im Neuenheimer Feld 583, Heidelberg

Activation of CD27 and other TNF receptor superfamily (TNFRSF) members is an attractive approach to stimulate anti-cancer immune response
The proprietary trivalent single-chain CD27 ligand (scCD27L) module allows the construction of hexavalent systemic – and bispecific tumor-targeted molecules
The unique properties of the trivalent scCD27L module enables the development of attractive drug candidates superior to other approaches
The bispecific SAB construction principle is a platform approach and ready to be applied to different TNFSF ligands (4-1BBL, GITRL, CD40L, LIGHT) and/or tumor targets